What is Spero Therapeutics, Inc.'s Shariah compliance score?

Spero Therapeutics, Inc.'s (SPRO) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Spero Therapeutics, Inc. pass AAOIFI screening?

Spero Therapeutics, Inc. (SPRO) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (SPRO: 4.1%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Spero Therapeutics, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Spero Therapeutics, Inc. (SPRO) using the latest financial data.

Where can I screen Spero Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Spero Therapeutics, Inc. (SPRO) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about SPRO's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

SPRO: Is Spero Therapeutics, Inc. Halal?

Spero Therapeutics, Inc.

NASDAQHealthcareUS

$1.23

+1.23%

Market Cap: 71.2M

Compliance Status

Not Halal

Screened on Aug 26, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Spero Therapeutics, Inc. (SPRO) halal? Not Halal. Based on AAOIFI screening, Spero Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

4.1% of 30.0% limit

What this means for you

Most scholars advise not holding SPRO

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 26, 2026

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

RGCA+

Regencell Bioscience Holdings Limited

$5.02

-4.92%

0001.KLA+

Supercomnet Technologies Bhd

$0.52

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

-0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.38

-0.01%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track SPRO and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Spero Therapeutics, Inc. (SPRO) halal to invest in?

Spero Therapeutics, Inc. (SPRO) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Spero Therapeutics, Inc. get a F compliance rating?

Spero Therapeutics, Inc. (SPRO) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 4.1% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Spero Therapeutics, Inc.'s Shariah verdict?

Spero Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Spero Therapeutics, Inc. re-screened for Shariah compliance?

Spero Therapeutics, Inc. (SPRO) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 26, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.